Arvinas Inc

ARVN is in an early Stage 1 consolidation following a terminal decline, with a Bullish Pivot Point pattern signaling failure of downside control and structural repair toward a higher equilibrium. The medium-term bias is bullish within this emerging base, but short-term conditions are extended near the upper boundary and RSI is overbought. Execution should be deferred, stalking for a pullback and absorption around the rising 9/20 EMA zone near prior resistance.

• ↑FDA approval of Veppanu treats ESR1 mutant ER+ breast cancer, marking first PROTAC therapeutic approved.
• ↑Q1’26 cash balance of $614.9M funds operations through mid-2028, underpinning ongoing trials and pipeline expansion.
• ↓Q1’26 revenue fell 91.7% YoY to $15.6M, driven by reduced Pfizer collaboration income.